- Home
- FORA vs ANL Comparison
FORA vs ANL Comparison
Compare FORA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FORA | ANL |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.2M | 350.9M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FORA | ANL |
|---|---|---|
| Price | $2.10 | $8.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 21.3K | ★ 446.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,153,263.00 | N/A |
| Revenue This Year | $51.82 | N/A |
| Revenue Next Year | $7.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.64 | $0.88 |
| 52 Week High | $2.71 | $12.09 |
Technical Indicators
Market Signals| Indicator | FORA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 52.82 |
| Support Level | $2.05 | $1.36 |
| Resistance Level | $2.12 | $12.09 |
| Average True Range (ATR) | 0.02 | 0.82 |
| MACD | 0.00 | -0.47 |
| Stochastic Oscillator | 25.00 | 36.73 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.